Edesa Biotech (EDSA) Accounts Payables (2013 - 2026)
Edesa Biotech (EDSA) posted Accounts Payables of $756163.0 for Q4 2025, down 29.89% sequentially from $1.1 million in Q3 2025, and down 60.21% YoY from $1.9 million in Q4 2024.
Edesa Biotech (EDSA) Accounts Payables (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Accounts Payables for 13 years, with the latest figure at $756163.0 in Q4 2025.
- Quarterly Accounts Payables fell 60.21% year-over-year to $756163.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $756163.0 (down 60.21% YoY) and the FY2025 annual result came in at $1.1 million, down 40.51% from the prior year.
- Accounts Payables retreated to $756163.0 in Q4 2025 per EDSA's latest filing, from $1.1 million in the prior quarter.
- Over five years, Accounts Payables peaked at $5.6 million in Q2 2022 and troughed at $672674.0 in Q2 2025.
- A 5-year average of $1.9 million and a median of $1.7 million in 2021 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2021 and 2023: Accounts Payables jumped 780.04% in 2021, then sank 74.11% in 2023.
- Over 5 years, Accounts Payables stood at $1.7 million in 2021, then decreased by 27.37% to $1.2 million in 2022, then surged by 57.67% to $1.9 million in 2023, then dropped by 0.44% to $1.9 million in 2024, then slumped by 60.21% to $756163.0 in 2025.
- According to Business Quant data, Accounts Payables over the past three periods registered $756163.0, $1.1 million, and $672674.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 3.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.91 Mn |
| Dec 31, 2025 | 756,163.00 |
| Sep 30, 2025 | 1.08 Mn |
| Jun 30, 2025 | 672,674.00 |
| Mar 31, 2025 | 914,701.00 |
| Dec 31, 2024 | 1.90 Mn |
| Sep 30, 2024 | 1.81 Mn |
| Jun 30, 2024 | 2.32 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 1.91 Mn |
| Sep 30, 2023 | 1.75 Mn |
| Jun 30, 2023 | 1.45 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 2.12 Mn |
| Jun 30, 2022 | 5.62 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Dec 31, 2021 | 1.67 Mn |
| Sep 30, 2021 | 1.38 Mn |
| Jun 30, 2021 | 903,964.00 |